Lantheus (LNTH) Trading Down 5.6% on Insider Selling

Share on StockTwits

Shares of Lantheus Holdings Inc (NASDAQ:LNTH) traded down 5.6% on Friday after an insider sold shares in the company. The company traded as low as $23.98 and last traded at $24.25. 602,262 shares were traded during mid-day trading, an increase of 87% from the average session volume of 322,160 shares. The stock had previously closed at $25.70.

Specifically, Director A Frederick Robertson sold 3,932 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $22.77, for a total value of $89,531.64. Following the completion of the transaction, the director now directly owns 43,062 shares of the company’s stock, valued at approximately $980,521.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Cesare Orlandi sold 3,111 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $23.10, for a total transaction of $71,864.10. Following the completion of the transaction, the insider now directly owns 87,115 shares of the company’s stock, valued at $2,012,356.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 120,102 shares of company stock valued at $2,942,398. 2.60% of the stock is owned by corporate insiders.

A number of equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 22nd. Zacks Investment Research upgraded shares of Lantheus from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Wednesday, February 20th. TheStreet upgraded shares of Lantheus from a “c+” rating to a “b” rating in a research note on Monday, March 4th. Finally, ValuEngine upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.33.

The company has a market capitalization of $991.08 million, a price-to-earnings ratio of 25.80, a PEG ratio of 1.92 and a beta of 1.52. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.03. Lantheus had a net margin of 12.17% and a return on equity of 59.57%. The firm had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. As a group, research analysts expect that Lantheus Holdings Inc will post 1.11 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. LSV Asset Management grew its position in Lantheus by 84.7% in the 4th quarter. LSV Asset Management now owns 1,599,532 shares of the medical equipment provider’s stock worth $25,032,000 after purchasing an additional 733,611 shares during the last quarter. Mesirow Financial Investment Management Equity Management bought a new position in Lantheus in the 4th quarter worth about $6,922,000. Renaissance Technologies LLC grew its position in Lantheus by 42.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,435,600 shares of the medical equipment provider’s stock worth $35,143,000 after purchasing an additional 427,800 shares during the last quarter. Peregrine Capital Management LLC grew its position in Lantheus by 47.4% in the 4th quarter. Peregrine Capital Management LLC now owns 837,108 shares of the medical equipment provider’s stock worth $13,101,000 after purchasing an additional 269,334 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Lantheus in the 1st quarter worth about $4,528,000. Hedge funds and other institutional investors own 92.98% of the company’s stock.

WARNING: “Lantheus (LNTH) Trading Down 5.6% on Insider Selling” was posted by Macon Daily and is the property of of Macon Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://macondaily.com/2019/05/17/lantheus-lnth-trading-down-5-6-on-insider-selling.html.

About Lantheus (NASDAQ:LNTH)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

See Also: Discount Rate

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.